Targeting the retromer for therapeutic manipulation in neurodegenerative disease is one promising approach, given the availability of small molecule chaperones that bind Vps29 (Mecozzi et al., 2014; Vagnozzi et al., 2019; Young et al., 2018). The gene discussed is VPS29; the disease is neurodegenerative disease.